A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells

BACKGROUND: Mesenchymal stromal cells (MSCs) are multipotent progenitor cells used in several cell therapies. MSCs are characterized by the expression of CD73, CD90, and CD105 cell markers, and the absence of CD34, CD45, CD11a, CD19, and HLA-DR cell markers. CD90 is a glycoprotein present in the MSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Moraes, Daniela A., Sibov, Tatiana T., Pavon, Lorena F., Alvim, Paula Q., Bonadio, Raphael S., Da Silva, Jaqueline R., Pic-Taylor, Aline, Toledo, Orlando A., Marti, Luciana C., Azevedo, Ricardo B., Oliveira, Daniela M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964048/
https://www.ncbi.nlm.nih.gov/pubmed/27465541
http://dx.doi.org/10.1186/s13287-016-0359-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964048/
https://www.ncbi.nlm.nih.gov/pubmed/27465541
http://dx.doi.org/10.1186/s13287-016-0359-3

Ejemplares similares